Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

910 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.
Van Tine BA, Ingham MA, Attia S, Meyer CF, Baird JD, Brooks-Asplund E, D'Silva D, Kong R, Mwatha A, O'Keefe K, Weetall M, Spiegel R, Schwartz GK. Van Tine BA, et al. Among authors: kong r. J Clin Oncol. 2024 Apr 29:JCO2301684. doi: 10.1200/JCO.23.01684. Online ahead of print. J Clin Oncol. 2024. PMID: 38684039
Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors.
Shapiro GI, O'Mara E, Laskin OL, Gao L, Baird JD, Spiegel RJ, Kaushik D, Weetall M, Colacino J, O'Keefe K, Branstrom A, Goodwin E, Infante J, Bedard PL, Kong R. Shapiro GI, et al. Among authors: kong r. Clin Pharmacol Drug Dev. 2021 Aug;10(8):940-949. doi: 10.1002/cpdd.904. Epub 2021 Jan 13. Clin Pharmacol Drug Dev. 2021. PMID: 33440067 Clinical Trial.
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent.
Jernigan F, Branstrom A, Baird JD, Cao L, Dali M, Furia B, Kim MJ, O'Keefe K, Kong R, Laskin OL, Colacino JM, Pykett M, Mollin A, Sheedy J, Dumble M, Moon YC, Sheridan R, Mühlethaler T, Spiegel RJ, Prota AE, Steinmetz MO, Weetall M. Jernigan F, et al. Among authors: kong r. Mol Cancer Ther. 2021 Oct;20(10):1846-1857. doi: 10.1158/1535-7163.MCT-20-0774. Epub 2021 Jul 26. Mol Cancer Ther. 2021. PMID: 34315764 Free PMC article. Clinical Trial.
Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
Branstrom A, Cao L, Furia B, Trotta C, Santaguida M, Graci JD, Colacino JM, Ray B, Li W, Sheedy J, Mollin A, Yeh S, Kong R, Sheridan R, Baird JD, O'Keefe K, Spiegel R, Goodwin E, Keating S, Weetall M. Branstrom A, et al. Among authors: kong r. Front Oncol. 2022 Feb 9;12:832816. doi: 10.3389/fonc.2022.832816. eCollection 2022. Front Oncol. 2022. PMID: 35223511 Free PMC article.
The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines.
Luban J, Sattler RA, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, Suder EL, Wang Y, Soloveva V, Cintron-Lue K, Naryshkin NA, Pykett M, Welch EM, O'Keefe K, Kong R, Goodwin E, Jacobson A, Paessler S, Peltz SW. Luban J, et al. Among authors: kong r. Virus Res. 2021 Jan 15;292:198246. doi: 10.1016/j.virusres.2020.198246. Epub 2020 Nov 26. Virus Res. 2021. PMID: 33249060 Free PMC article.
910 results